Monoclonal antibodies have also been tested in animal models of cardiovascular disease (coronary thrombosis, stroke, and in-stent stenosis): GPG-290, 6B4-Fab, h6B4-Fab, and AJW200 directly target the VWF-GpIb binding; 82D6A3 blocks VWF-collagen interaction; and finally, SZ-123 inhibits both mechanisms [102–109]. This evidence concerns the gene VWF and stroke disorder.